The Retatrutide Revolution: A Visual Guide to the Latest Clinical Trial Data
Jun 16th 2025
The Retatrutide Revolution
A Visual Guide to the Latest Clinical Trial Data for Researchers
What is Retatrutide?
An investigational tri-agonist therapy, also known as "Triple G," that targets three hormone receptors in a single molecule for unprecedented metabolic impact.
A Unique Tri-Agonist Mechanism
GLP-1 Agonism
Promotes satiety, enhances insulin secretion, and slows digestion.
GIP Agonism
Augments GLP-1 effects and helps regulate lipid metabolism.
Glucagon Agonism
Increases energy expenditure and fat burning.
Unprecedented Phase 2 Results
Obesity Trial (NEJM)
24.2%
Mean body weight reduction at 48 weeks.
Weight loss had not plateaued at 48 weeks.
Type 2 Diabetes Trial (Lancet)
16.9%
Body weight reduction
-2.02%
HbA1c reduction
Suggests potential to overcome metabolic resistance.
Broad Cardiometabolic Benefits
Liver Fat Reduction
93% of patients reversed MASLD indicators.
Blood Pressure
Significant dose-dependent reduction in blood pressure.
Lipid Profile
Improved triglyceride and LDL levels.
The Future is TRIUMPHant
The Phase 3 TRIUMPH program may validate Retatrutide as a non-surgical alternative to bariatric procedures, with potential for treating cardiovascular disease, sleep apnea, and osteoarthritis.